MAPT and Alzheimer disease: Recently, the first lipidomic profiling of cerebrospinal fluid in AD was undertaken to simultaneously analyze both SPMs and classical eicosanoids in patients with cognitive impairment, ranging from subjective impairment to a diagnosis of AD, and correlated to cognition, CSF tau, and β-amyloid.